Clinical trial · Interventional
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension
NCT01234922CI-TRIAL-00034601terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure. PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypertension | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| benazepril hydrochloride | Drug | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| lisinopril | Drug | — | UNRESOLVED |
| losartan potassium | Drug | — | UNRESOLVED |
| ramipril | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients receive oral benazepril hydrochloride once daily on days 1-7.
- interventionNames
- Other: laboratory biomarker analysis
- Drug: benazepril hydrochloride
- type
- EXPERIMENTAL
- label
- Arm II
- description
- Patients receive oral lisinopril once daily on days 1-7.
- interventionNames
- Drug: lisinopril
- Other: laboratory biomarker analysis
- type
- EXPERIMENTAL
- label
- Arm III
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure \> 130 OR a diastolic pressure \> 80 * Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy * Creatinine \< 2.5 * Potassium \< ULN * Ability to understand and the willingness to sign a written informed consent document * HIV positive patients are eligible to participate in this study Exclusion Criteria: * Patients who are pregnant or nursing due to significant risk to the fetus/infant * Patients who are unable to take oral medications * Patients who are currently taking an ACE-Inhibitor or ARB
References
Publications (0)
Data not yet available
No reference posted for this study.